Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis

The First Affiliated Hospital of Dalian Medical University30 enrolled

Overview

To investigate the safety and efficacy of umbilical cord mesenchymal stem cell transplantation in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Lupus nephritis (LN) is one of the most serious complications of SLE. The current clinical treatments of LN mainly include steroids and immunosuppressive drugs, but drug side effects are obvious.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Lupus Nephritis

Interventions

SLE groupBIOLOGICAL

The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.

LN groupBIOLOGICAL

The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.

the control groupOTHER

The patients will be assigned to the control group.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meeting the 1997 American College of Rheumatology (ACR) classification criteria of SLE. * age 18-60 years. * of either sex and of any ethnicity. * Lupus nephritis (LN) group: (1) Receiving more than 6 months of regular treatment, 24-hour urine protein ≥ 1.0 g, serum creatinine ≥1.5 mg/dL; (2) renal biopsy: class III, IV or V LN included, and class VI excluded. * After conventional treatment (glucocorticoid therapy and immunosuppressive drugs) prior to grouping, SLEDAI scores ≥ 10. * Receiving 12 months of treatment while using birth control. * Provision of informed consent. Exclusion Criteria: * Poor blood pressure control by drug treatment (≥ 160/100 mmHg) * Abnormal hepatic function (a 3-fold increase in alanine aminotransferase level relative to normal liver). * Renal failure (glomerular filtration rate \< 15 mL/min/1.73 m2). * Severe heart and lung failure, or injury to other important organs * Uncontrollable infection. * Having not taken biological agents for 6 months. * Pregnant or lactating women, or those women who are trying to get pregnant or those men who are trying to make their partners pregnant.

Outcomes

Primary Outcomes

SLEDAI-2000 score

The SLEDAI 2000 is a novel index that measures ≥ 50% in each of the 24 descriptors of SLEDAI-2K and generates a total score reflecting disease activity overall.

Time frame: changes of month 3, month 6, month 9 and month 12 after treatment

Secondary Outcomes

BILAG-2004 score

The BILAG-2004 is a comprehensive composite clinical index that has been recently validated for the assessment of systemic lupus erythematosus (SLE) disease activity. This index is based on the Classic BILAG index and has many similarities with its predecessor: it is based on the principle of the physician's intention to treat, has transitional property that captures changing severity of clinical manifestations and has a similar ordinal scale scoring system. However, it has nine systems and many of the changes (from the Classic BILAG index) are in the items, glossary and scoring scheme. As with the Classic BILAG index, the individual system scores were not intended to be summated into a global score.

Time frame: changes of month 3, month 6, month 9 and month 12 after treatment

Health Assessment Questionnaire (HAQ) score

The Health Assessment Questionnaire (HAQ) has played an influential role in establishing health outcome assessment as a quantifiable set of reliable, valid and responsive hard data points. The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality. It has been validated by mail, in the office, by telephone, and by comparison with paraprofessional and physician judgments as a reliable instrument, and has been significantly correlated with other PRO instruments. Typically, one of two HAQ versions is used: the Full HAQ, which assesses all five dimensions, and the Short or 2-page HAQ, which contains only the HAQ disability index (HAQ-DI) and the HAQ's patient global and pain visual analog scales (VAS).

Time frame: changes of month 3, month 6, month 9 and month 12 after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.